Boston Scientific Corp. (BSX)

36.47
NYSE : Health Technology
Prev Close 36.47
Day Low/High 0.00 / 0.00
52 Wk Low/High 24.54 / 39.44
Avg Volume 7.01M
Exchange NYSE
Shares Outstanding 1.38B
Market Cap 50.73B
EPS 0.10
P/E Ratio 75.44
Div & Yield N.A. (N.A)

Latest News

Boston Scientific Announces Results For Third Quarter 2018

Boston Scientific Announces Results For Third Quarter 2018

MARLBOROUGH, Mass., Oct.

Boston Scientific Prevails In German Edwards Lifesciences Litigation

Boston Scientific Prevails In German Edwards Lifesciences Litigation

Court Rules Edwards Lifesciences' Next-Generation Valve Infringes Boston Scientific Patent and Grants Right to Enjoin Sales in Germany

Boston Scientific Closes Acquisition Of Augmenix, Inc.

Boston Scientific Closes Acquisition Of Augmenix, Inc.

MARLBOROUGH, Mass., Oct.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Boston Scientific Receives U.S. FDA Approval For The Eluvia™ Drug-Eluting Vascular Stent System

Boston Scientific Receives U.S. FDA Approval For The Eluvia™ Drug-Eluting Vascular Stent System

First peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease

Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial

Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries

Boston Scientific Launches LithoVue Empower™ Retrieval Deployment Device

Boston Scientific Launches LithoVue Empower™ Retrieval Deployment Device

New Data at World Congress of Endourology Demonstrate the LithoVue Empower Device Improves OR Experience

Jim Cramer: Here's Why the Market Rally Has Staying Power

Jim Cramer: Here's Why the Market Rally Has Staying Power

For most of this year the market has been led by growth stocks.

Jim Cramer: Valuations Now Have No Relation to Common Sense

Jim Cramer: Valuations Now Have No Relation to Common Sense

Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.

How Boston Scientific Call Prices Rose Eightfold

How Boston Scientific Call Prices Rose Eightfold

The Healthcare sector has seen a revitalization year-to-date, and these investors may have wanted to participate in a continued move higher, risking a fraction of the price of a share in the event they were 'late to the party.'

Boston Scientific Announces Agreement To Acquire Augmenix, Inc.

Boston Scientific Announces Agreement To Acquire Augmenix, Inc.

Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients

3 Biotech Stock Favorites to Bet on Today: Top Analysts

3 Biotech Stock Favorites to Bet on Today: Top Analysts

Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Boston Scientific Announces Agreement To Acquire VENITI, Inc.

Boston Scientific Announces Agreement To Acquire VENITI, Inc.

Acquisition to Bolster Company's Venous Therapies Portfolio within Peripheral Interventions Division

Boston Scientific Closes Acquisition Of Claret Medical, Inc., Announces Positive Reimbursement Decision

Boston Scientific Closes Acquisition Of Claret Medical, Inc., Announces Positive Reimbursement Decision

CMS Grants NTAP Designation for The Sentinel® Cerebral Protection System

Boston Scientific To Participate In 38th Annual Canaccord Genuity Growth Conference

Boston Scientific To Participate In 38th Annual Canaccord Genuity Growth Conference

MARLBOROUGH, Mass., July 30, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 in Boston.

Boston Scientific Announces Results For Second Quarter 2018

Boston Scientific Announces Results For Second Quarter 2018

MARLBOROUGH, Mass., July 25, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.

Boston Scientific Corporation Recommends Stockholders Reject 'Mini-Tender' Offer By TRC Capital Corporation

Boston Scientific Corporation Recommends Stockholders Reject 'Mini-Tender' Offer By TRC Capital Corporation

MARLBOROUGH, Mass., July 24, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to three million shares of Boston Scientific's common...

Boston Scientific Announces Agreement To Acquire Claret Medical, Inc.

Boston Scientific Announces Agreement To Acquire Claret Medical, Inc.

Addition of FDA-cleared Sentinel® Cerebral Embolic Protection System to Expand Company's Structural Heart Offerings

Boston Scientific To Acquire Cryterion Medical, Inc.

Boston Scientific To Acquire Cryterion Medical, Inc.

Company to expand atrial fibrillation ablation therapy offerings with innovative cryoballoon platform

Boston Scientific Announces Conference Call Discussing Second Quarter 2018 Financial Results

Boston Scientific Announces Conference Call Discussing Second Quarter 2018 Financial Results

MARLBOROUGH, Mass., July 2, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2018 on Wednesday, July 25, 2018 at 8:00...

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

The heart-implant manufacturer is down some 4% over two days, but is up 128% year to date.

Magellan Midstream, Xylem, Boston Scientific: 'Mad Money' Lightning Round

Magellan Midstream, Xylem, Boston Scientific: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Magellan Midstream Partners, Xylem, Boston Scientific, Karyopharm Thereapeutics, Iovance Biotherapeutics, Casella Waste Systems and more.

TheStreet Quant Rating: A- (Buy)